海泰新光：国药新光的整机产品2024年第二季度获批，目前销售数量还不多

Group 1 - The core point of the article is the performance outlook of the joint venture between the company and Sinopharm, known as Sinopharm Xinguang, and its efforts to improve profitability in 2024 [2] - Sinopharm Xinguang's complete machine products are expected to be approved in the second quarter of 2024, with sales promotion starting in the second half of the year [2] - The company has intensified the promotion of endoscopes this year, receiving initial recognition from users [2] - Sinopharm Xinguang is also expanding its product range to enhance profitability [2]